SPS 2009 Sponsors

Diamond
($15,000+)

Emerald
($10,000 to $14,999)

Ruby
($6,000 to $9,999)

Opal
($3,000 to $5,999)

Sapphire
(Up to $2,999)

Lewis B. Kinter & Terry Timberlake-Kinter

Distinguished Service Award

The Distinguished Service Award Deadline is extended to January 30, 2009

This award is to honor an individual who has substantially contributed to the field of Safety Pharmacology.

For a nomination, the following criteria will be considered:

Specific research achievements
Champions of the field
Lifelong contribution to the field
Substantial specific contribution
Visionary direction
Regulatory decisions
Science of the field
Education
Collaboration between industry and academia

The Distinguished Service Award (DSA) will be given every year, although there shall be no obligation or duty to make such award when, in the sole opinion of the committee, there is no qualified nominee.

Nominations
Only Members may nominate although the nominee does not have to be a member. A member may not nominate more than one person per year.

Nominations must contain name of nominee, current position and address, and current e-mail address, at least three letters of support, a current Curriculum Vitae, and supporting documentation that indicates the nominee's achievements in safety pharmacology (critical in the review of each nominee). Electronic (Word or PDF) or FAXed copy of the nomination should be sent to SPS Headquarters.

The Award
Presentation of the Award will be given at the Annual Meeting of the Society. The recipient will be given a plaque, a cash award, and an invitation to deliver a presentation that may be published with the meeting proceedings. Travel expenses for the recipient to attend the meeting will be paid.

2008 Distinguished Service Award Winner

Peter K.S. Siegl, Ph.D.

Dr. Siegl has practical knowledge of and extensive experience in drug discovery, drug development and regulatory strategy based upon his 26+ year tenure at Merck Research Laboratories (MRL) as well as active participation in professional scientific societies and professional organizations. He received his training as a pharmacologist at Philadelphia College of Pharmacy and Science and the University of British Columbia (Faculty of Pharmaceutical Sciences). Dr. Siegl has actively contributed to the external scientific and regulatory drug development landscape. He has more than 100 scientific publications in peer review journals and several book chapters. He is one of the founders and was first president of the Safety Pharmacology Society (2001). He chaired the ILSI/Health and Environmental Science Institute Cardiovascular Safety Subcommittee (2002–2006) and was Deputy Topic Leader representing PhRMA on the International Conference on Harmonization: Topic ICH S7B, "Guideline on Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals". He was a Safety Pharmacology Technical Group Co-Leader in the PhRMA DruSafe (Drug Safety) Committee (2000–2007). Dr. Siegl is currently an independent consultant focusing on risk assessments for new drug discovery and development programs.

Safety & Secondary Pharmacology Past, Present & Future—(Member only access)

The DSA Committee
The President will, in January, appoint a committee of 4, and either Chairs the committee or appoints a chair, making a five-person committee.

The Committee will draft a notice soliciting nominations that will be sent to the membership and posted on the Web site the second week of October.

Nominations are due by January 12. The Committee will review the nominations, have a teleconference in January and make a decision by Feburary 11. The winner will be notified no later than Feburary 21 by letter from the President and/or the Chair of the Committee.